Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Sleep Apnea01:21

Sleep Apnea

Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Event rates of patients with stable heart failure with reduced ejection fraction and newly diagnosed obstructive or central sleep apnoea.

European journal of heart failure·2026
Same author

Baroreflex activation therapy for resistant hypertension: promise present or passed?

Journal of hypertension·2026
Same author

Discordant ventilatory and efferent sympathetic responsiveness to peripheral and central chemoreflex stimulation in heart failure with reduced ejection fraction.

European journal of heart failure·2026
Same author

Reflex Neurogenic Vasoconstriction When Patients With Heart Failure Exercise: Are Females More Sympathetic Than Males?

JACC. Advances·2026
Same author

Win Ratio Analysis for Peak-Flow Adaptive Servoventilation in Treating Sleep Apnoea in Heart Failure With Reduced Ejection Fraction.

The Canadian journal of cardiology·2026
Same author

Comment on ERS/ESRS statement on adaptive servo-ventilation for treatment of central sleep apnoea.

The European respiratory journal·2026

関連する実験動画

Updated: Jun 26, 2026

Acupoint Application Combined with Ear Plaster Therapy for Treating Sleep Disorders with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
04:53

Acupoint Application Combined with Ear Plaster Therapy for Treating Sleep Disorders with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Published on: October 18, 2024

阻害性睡眠無呼吸症とその心血管への影響

T Douglas Bradley1, John S Floras

  • 1Sleep Research Laboratory of the Toronto Rehabilitation Institute, Toronto, Canada.

Lancet (London, England)
|December 23, 2008
PubMed
まとめ

阻害性睡眠無呼吸 (OSA) は,心臓血管の健康に重大な影響を及ぼし,高血圧や心不全などの疾患のリスクを高めます. OSAの治療はこれらのリスクを軽減する可能性があるが,改善された心血管疾患のアウトカムを確認するために大規模な試験が必要である.

科学分野:

  • 心臓病学 心臓病学
  • スリープ・メディシン (睡眠医学)
  • 内科内科は,内科の内科である.

背景:

  • 阻害性睡眠時無呼吸症 (OSA) は,睡眠中に繰り返される呼吸停止を伴う.
  • これらの出来事は,低酸素,負の胸内圧,および興奮を引き起こし,心臓血管系にストレスを与える.
  • OSAは,高血圧,冠動脈疾患,心不全,脳卒中のリスクの増加と関連しています.

研究 の 目的:

  • 阻害性睡眠無呼吸症の心血管への影響を検討する.
  • 心血管の健康に対するOSA治療の潜在的な利点の評価をするために.
  • さらに大規模な臨床試験の必要性を特定する.

主な方法:

  • OSAと心血管疾患に関する疫学研究のレビュー.
  • OSAに対する継続的な陽性気道圧 (CPAP) 治療を調査するランダム化試験からのデータの分析.
  • OSAと心血管疾患を結びつける病理生理学的メカニズムに関する現在の証拠の統合.

主要な成果:

  • OSAは,低酸素,交感活性化,炎症を含む有害な心血管刺激を誘発する.
  • CPAPによる治療は,心不全患者の血圧の低下や心機能の改善などの利点を示しています.

さらに関連する動画

Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea
07:54

Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

関連する実験動画

Last Updated: Jun 26, 2026

Acupoint Application Combined with Ear Plaster Therapy for Treating Sleep Disorders with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
04:53

Acupoint Application Combined with Ear Plaster Therapy for Treating Sleep Disorders with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Published on: October 18, 2024

Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea
07:54

Drug-Induced Sleep Endoscopy (DISE) with Target Controlled Infusion (TCI) and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

  • 流行病学的データは,OSAと主要な心血管疾患を強く関連付けています.

    • 結論:

    • 阻害性睡眠無呼吸症は,心血管疾患の重要な危険因子です.
    • OSAの治療,特にCPAPによる治療は,心血管疾患のリスクを軽減することに有望であることが示されています.
    • さらに大規模なランダム化試験は,OSA治療が心血管疾患のアウトカムを改善するかどうかを決定的に確立するために不可欠です.